Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review

Xiaodan Lv, Yongqiang Dong, Lingling Hu, Feiyu Lu, Changyu Zhou, Shaoyou QinEndocrinology 2020 · DOI

TL;DR

This systematic review synthesizes evidence from 24 clinical trials to assess the effectiveness of GLP-1 receptor agonists (GLP-1 RAs) in managing nonalcoholic fatty liver disease (NAFLD). The findings suggest GLP-1 RAs are promising for improving liver inflammation and steatosis, with potential to reverse fibrosis, highlighting a significant therapeutic avenue for this growing health concern.

What Problem Does This Paper Address?

Nonalcoholic fatty liver disease (NAFLD) is a widespread chronic liver condition, particularly prevalent in individuals with type 2 diabetes mellitus (T2DM). It ranges from simple fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. Currently, there are no FDA-approved drugs specifically for NAFLD, and treatment primarily relies on lifestyle interventions like weight loss, which are often difficult to sustain. This lack of effective pharmacological options, coupled with challenges in defining appropriate clinical trial endpoints (especially the invasive nature of liver biopsies), creates a significant unmet need for therapeutic strategies. This paper addresses this by systematically reviewing the existing evidence on GLP-1 receptor agonists (GLP-1 RAs), a class of drugs already used for diabetes and weight management, for their potential in treating NAFLD.

Methods

The researchers conducted a systematic review of published and ongoing clinical trials. They searched major databases (PubMed, Scopus, Web of Science, ClinicalTrials.gov, Cochrane CENTRAL, WHO ICTRP) up to November 2, 2019, using keywords related to GLP-1 RAs and NAFLD. The review included 24 clinical trials, encompassing a total of 6313 participants, with study durations ranging from 12 to 144 weeks. The primary focus was on evaluating the efficacy of GLP-1 RAs in improving histological findings (liver biopsy), noninvasive markers of hepatic steatosis, inflammation, and fibrosis, as well as insulin resistance and anthropometric measures. The quality of randomized controlled trials (RCTs) was assessed using a modified Cochrane Collaboration Risk of Bias Tool.

Datasets

Not discussed in the paper. The paper is a systematic review of existing clinical trial data, not a study that generates new datasets.

Key Insights and Ideas

  • GLP-1 RAs as a Multifaceted Therapeutic Agent: Beyond their established roles in diabetes and weight management, GLP-1 RAs are emerging as a promising treatment for NAFLD, addressing multiple facets of the disease.
  • Bridging the Gap in NAFLD Treatment: With no approved drugs for NAFLD, GLP-1 RAs offer a potential pharmacological intervention that targets key pathological processes.
  • The Challenge of Endpoints: The paper highlights the ongoing debate and challenges in defining optimal endpoints for NAFLD clinical trials, with liver biopsy being the gold standard but impractical for large-scale studies, leading to increased reliance on noninvasive markers.
  • Heterogeneity in Trial Design: The review notes significant variability in study designs, sample sizes, and durations across the included trials, which can impact the robustness of conclusions.
  • The Promise of Histological Improvement: While many studies relied on surrogate markers, the few that used liver histology showed encouraging results, particularly regarding the improvement of NASH features.

Key Results

The systematic review included 24 clinical trials involving 6313 participants, with a mean study duration of 37 weeks.

  • Hepatic Enzymes and Steatosis: GLP-1 RAs were found to be effective in improving elevated hepatic enzymes (ALT, AST, GGT) and hepatic steatosis.
  • Inflammation and Fibrosis: The agents showed efficacy in reducing hepatic inflammation and showed potential for reversing fibrosis.
  • NASH Improvement: Importantly, GLP-1 RAs demonstrated promise in improving the histological features of NASH.
  • Histological Endpoints: Out of 24 trials, only four used biopsy-confirmed liver histology as their primary endpoint. The remaining 20 used surrogate endpoints like changes in liver enzymes, steatosis markers, or fibrosis markers.
  • Ongoing Trials: Eight ongoing clinical trials were identified, with a notable trend towards using more sensitive endpoints like MRI assessment of hepatic steatosis, liver fibrosis, and biopsy-confirmed liver histology.

Limitations and Future Work

The authors acknowledge several limitations:

  • Heterogeneity: Significant heterogeneity in trial design, quality, sample size, and duration across the included studies.
  • Limited Histological Data: Only a small number of trials (four) used biopsy-confirmed liver histology as a primary endpoint, limiting definitive conclusions on histological improvement.
  • Surrogate Endpoints: The reliance on surrogate endpoints in many studies means that direct histological evidence of NASH resolution or fibrosis regression is not always available.
  • Need for Long-Term, Large-Scale Studies: The authors emphasize the critical need for well-designed, prospective, large-sample controlled trials with long-term follow-up and histological endpoints to fully assess the efficacy of GLP-1 RAs in managing NAFLD and NASH.

Future work should focus on these larger, more robust trials to confirm the promising findings and establish GLP-1 RAs as a standard treatment for NAFLD.

Summary updated

Abstract

There are no licensed drugs for nonalcoholic fatty liver disease (NAFLD), and there is a lack of consensus on the best outcome measures for controlled trials. This systematic review aimed to evaluate the efficacy of GLP-1 RAs in the management of NAFLD, the degree of heterogeneity in trial design and the robustness of conclusions drawn from these clinical trials. We searched publication databases and clinical trial registries through 2 November 2019 for clinical trials with NAFLD. We evaluated improvements in histological findings, noninvasive markers of hepatic steatosis, inflammation, and fibrosis, insulin resistance and anthropometric measures. Our final analysis included 24 clinical trials, comprising 6313 participants with a mean duration of 37 weeks. Four clinical trials, including RCT (n = 1), single-arm studies (n = 2) and case series studies (n = 1), used biopsy-confirmed liver histological change as their end-points. The remaining studies (n = 20) used surrogate end-points. GLP-1 RAs were effective for the improvement in hepatic inflammation, hepatic steatosis and fibrosis. More importantly, GLP-1 RAs showed promise in improving the histological features of NASH. In addition, 8 ongoing trials were identified. In this systematic review of published and ongoing clinical trials of the efficacy of GLP-1RAs for NAFLD, we found that GLP-1 RAs are effective for hepatic steatosis and inflammation, with the potential to reverse fibrosis. Further prospective studies of sufficient duration using histological end-points are needed to fully assess the efficacy of GLP-1 RAs in the management of NAFLD.
BibTeX
@inproceedings{lv2020glucagonlike,
  author = {Xiaodan Lv and Yongqiang Dong and Lingling Hu and Feiyu Lu and Changyu Zhou and Shaoyou Qin},
  title = {{Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review}},
  booktitle = {Endocrinology},
  year = {2020},
  doi = {10.1002/edm2.163},
}
Figure